Relmada Therapeutics Inc Share

$2.99

2.61% today

Nasdaq, Jul 02, 10:00 pm CET

ISIN

US75955J2042

Symbol

RLMD

Reports

Quarter | Year

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Relmada Therapeutics Inc Share price

$3.07

-4.21 57.83% 5Y

Nasdaq, Closing price Mon, Jul 01 2024

+0.07 2.33%

ISIN

US75955J2042

Symbol

RLMD

Reports

Quarter | Year

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$92.63m
Enterprise Value	$9.02m
PER (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	1.29
Turnover (TTM) Turnover	$0.00
EBIT (operating result TTM) EBIT	$-98.54m
Free cash flow (TTM) Free cash flow	$-48.19m
Cash position	$83.61m
EPS (TTM) EPS	$-3.13
P/E ratio expected	negative
Short interest	5.24%

As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.

Get Started for Free Today

Relmada Therapeutics Inc Share analysis

Unlock Scores for Free

??

4 Analysts have issued a Relmada Therapeutics Inc forecast:

2x Buy

50%

1x Hold

25%

1x Sell

25%

More details on analyst estimates including price targets

4 Analysts have issued a Relmada Therapeutics Inc forecast:

Buy

50%

Hold

25%

Sell

25%

Analyst estimates incl. share price targets

Financial data from Relmada Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter Annually

Assets

Mar '24
Current assets	84 84
Cash position	84 84
Claims	- -
Inventories	- -
Other current assets Other current assets Current assets	0.75 0.75

Fixed assets	0.04 0.04
Property, plant and equipment	- -
Financial assets	- -
Intangible assets	- -
Other fixed assets Other assets Fixed assets	0.04 0.04


Total assets	84 84

Liabilities

Mar '24
Equity	72 72

Debt capital	12 12
Current liabilities	12 12
Non-current liabilities	- -


Total capital	84 84

Figures in millions USD.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

Subscribe to news free of charge

Relmada Therapeutics Inc Share News

Neutral

Accesswire

●

about one hour ago

The Schall Law Firm Probes Relmada Therapeutics Inc For Possible Securities Violations And Urges Affected Investors To Contact

LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed t...

Neutral

Accesswire

●

4 days ago

The Schall Law Firm Is Investigating Relmada Therapeutics Inc For Potential Infringements Of Securities Regulations And Encourages Investors Who Experienced Losses To Make Contact

LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed ...

Neutral

Accesswire

●

6 days ago

The Schall Law Firm Is Probing Relmada Therapeutics Inc For Possible Breaches Of Securities Laws And Urges Investors Who Sustained Losses To Reach Out

LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed ...

More Relmada Therapeutics Inc News

Company profile

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of d-methadone receptor antagonist, which is a chemical entity that addresses areas of high unmet medical need in the treatment of central nervous system diseases and other disorders. The company was founded on May 31, 2012 and is headquartered in New York, NY.

Head office	United States
CEO	Sergio Traversa
Employees	20
Founded	2012
Website	www.relmada.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now